Document is current
Any future updates will be listed below
-
Authors
Zhang, Yin https://orcid.org/0000-0001-6367-6583
Wang, Qiao-Li
Yuan, Chen
Lee, Alice A. https://orcid.org/0000-0002-5241-1878
Babic, Ana
Ng, Kimmie https://orcid.org/0000-0003-0631-1494
Perez, Kimberly
Nowak, Jonathan A.
Lagergren, Jesper
Stampfer, Meir J.
Giovannucci, Edward L.
Sander, Chris
Rosenthal, Michael H.
Kraft, Peter https://orcid.org/0000-0002-4472-8103
Wolpin, Brian M. https://orcid.org/0000-0002-0455-1032
- License Information
-
More Information
Article History
Received: 16 August 2022
Accepted: 11 April 2023
First Online: 28 April 2023
Competing interests
: K.N. declares institutional research funding from Revolution Medicines, Pharmavite, Evergrande Group, and Janssen outside the submitted work, and consulting/advisory board fees from SeaGen, BiomX, Bicara Therapeutics, X-Biotix Therapeutics, and Redesign Health, outside the submitted work. K.P. declares advisory board fees from Celgene, Eisai, and Helsinn/QED, outside the submitted work. B.M.W. declares research funding from Celgene, Eli Lilly, and Company, Novartis, and Revolution Medicine, and consulting for Celgene, GRAIL, and Mirati outside the submitted work. Other authors declare no potential conflicts of interest.
